Health Catalyst (NASDAQ:HCAT) Given New $2.75 Price Target at Citigroup

Health Catalyst (NASDAQ:HCAT) had its price objective reduced by equities researchers at Citigroup from $3.25 to $2.75 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Citigroup’s price target would suggest a potential upside of 14.35% from the stock’s previous close.

Several other research firms have also weighed in on HCAT. William Blair restated an “outperform” rating on shares of Health Catalyst in a report on Tuesday, November 11th. Cantor Fitzgerald restated a “neutral” rating and set a $4.00 price objective on shares of Health Catalyst in a research note on Tuesday, October 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Health Catalyst in a research note on Monday, December 29th. Evercore ISI reduced their price target on Health Catalyst from $4.00 to $3.00 and set an “in-line” rating on the stock in a research report on Wednesday, October 8th. Finally, KeyCorp lowered their price objective on shares of Health Catalyst from $5.00 to $4.00 and set an “overweight” rating for the company in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $4.32.

Health Catalyst Trading Down 1.8%

HCAT stock traded down $0.05 during trading on Friday, reaching $2.41. 69,699 shares of the stock traded hands, compared to its average volume of 445,232. The firm has a market capitalization of $170.11 million, a PE ratio of -1.51 and a beta of 1.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.88 and a quick ratio of 1.88. The business’s 50 day moving average price is $2.56 and its 200-day moving average price is $3.08. Health Catalyst has a 52-week low of $2.02 and a 52-week high of $7.25.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Monday, November 10th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.01. The business had revenue of $76.32 million during the quarter, compared to analysts’ expectations of $75.05 million. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%. As a group, sell-side analysts forecast that Health Catalyst will post -0.33 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Julie Larson-Green sold 47,997 shares of the company’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $2.67, for a total value of $128,151.99. Following the sale, the director directly owned 73,573 shares of the company’s stock, valued at $196,439.91. This represents a 39.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Benjamin Landry sold 27,425 shares of the firm’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $2.64, for a total transaction of $72,402.00. Following the transaction, the general counsel directly owned 100,000 shares of the company’s stock, valued at approximately $264,000. This represents a 21.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. First Light Asset Management LLC increased its holdings in shares of Health Catalyst by 17.2% in the 2nd quarter. First Light Asset Management LLC now owns 12,230,181 shares of the company’s stock valued at $46,108,000 after acquiring an additional 1,793,374 shares during the last quarter. Millennium Management LLC boosted its holdings in Health Catalyst by 2,513.3% in the third quarter. Millennium Management LLC now owns 1,589,536 shares of the company’s stock worth $4,530,000 after purchasing an additional 1,528,710 shares during the period. Acadian Asset Management LLC increased its stake in Health Catalyst by 88.8% during the first quarter. Acadian Asset Management LLC now owns 930,229 shares of the company’s stock valued at $4,211,000 after purchasing an additional 437,536 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Health Catalyst by 53.6% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,066,396 shares of the company’s stock worth $4,020,000 after purchasing an additional 372,035 shares during the period. Finally, AMH Equity Ltd lifted its position in shares of Health Catalyst by 54.5% in the 3rd quarter. AMH Equity Ltd now owns 660,000 shares of the company’s stock worth $1,881,000 after buying an additional 232,851 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.